BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20647708)

  • 21. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
    Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
    Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
    Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
    Guan ZZ; Liu DG; Yu BM; Wu WQ; Shi D; Zhao Y; Wei YQ; Zou LQ; Wu XD; Zhuang W; Feng FY; Zhang P; Yu SY; Xiong HH; Fu Q; Zheng S; Huang JJ; Wu G; Yang CY; Sun SR; Ruan QL
    Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):119-21. PubMed ID: 15059335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
    Shin SJ; Jeung HC; Ahn JB; Choi HJ; Cho BC; Rha SY; Yoo NC; Roh JK; Chung HC
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):157-65. PubMed ID: 17426971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
    Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
    Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer.
    Ardavanis AS; Ioannidis GN; Orphanos GS; Rigatos GA
    Anticancer Res; 2006; 26(2B):1669-72. PubMed ID: 16619589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
    Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
    Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
    Blum JL; Kohles J; McKenna E; Scotto N; Hu S; Odom D; Kaye JA; Glück S
    Breast Cancer Res Treat; 2011 Jan; 125(2):431-9. PubMed ID: 21042933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
    Pagliaro LC; Perez CA; Tu SM; Daliani DD
    Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase.
    Saif MW; Black G; Roy S; Bell D; Russo S; Eloubeidi MA; Steg A; Johnson MR; Zelterman D; Diasio RB
    Cancer J; 2007; 13(4):247-56. PubMed ID: 17762760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.
    Rischin D; Phillips KA; Friedlander M; Harnett P; Quinn M; Richardson G; Martin A
    Gynecol Oncol; 2004 May; 93(2):417-21. PubMed ID: 15099955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
    Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
    Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
    Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
    Debled M; Madranges N; Trainaud A; Floquet A; Donamaria C; Brouste V; Durand M; Mauriac L
    Oncology; 2009; 77(5):318-27. PubMed ID: 19940523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.
    Schwartzberg LS; Arena FP; Mintzer DM; Epperson AL; Walker MS
    Clin Breast Cancer; 2012 Apr; 12(2):87-93. PubMed ID: 22154117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.